Market: NASD |
Currency: USD
Address: Bellevue Centre
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Show more
📈 BriaCell Therapeutics Corp. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2020 |
- |
$0.003333 |
- |
2020-01-02 |
- |
Stock split |
|
Total Amount for 2020: $0.003333 |
📅 Earnings & EPS History for BriaCell Therapeutics Corp.
| Date | Reported EPS |
|---|
| 2025-06-16 | -16.4 |
| 2025-03-12 | -23.3 |
| 2024-12-16 | -33 |
| 2024-10-28 | -10.5 |
| 2024-06-14 | 16.5 |
| 2024-03-18 | -106.5 |
| 2023-12-14 | 54 |
| 2023-10-25 | -21 |
| 2023-06-14 | -48 |
| 2023-03-15 | -115.5 |
| 2022-12-14 | -10.5 |
| 2022-10-27 | -153 |
| 2022-06-13 | -48 |
| 2022-03-14 | -36 |
📰 Related News & Research
No related articles found for "briacell therapeutics".
